ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial ...
The BCG compression tee sees me through every type of workout: 400-meter repeats, tempo runs, hill sprints, as well as ...
As concerns over global policy uncertainty reached a 20-year peak in 2025, BCG is warning that the issue must be a core ...
The collaboration seeks to address this gap by transitioning organisations from limited experimentation to enterprise-wide ...
Enrollment Progress in QUILT-2.005 The QUILT-2.005 trial aims to evaluate the efficacy of ANKTIVA® in conjunction with BCG in patients who have not previously received BCG treatment. As of January ...
By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.
ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...
I was born and raised in India. On the day I was born, I am told I got my first jab, a vaccine called BCG (bacille Calmette-Guerin). Kids born in India today still get this vaccine. This century-old ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results